Talk:Dexcom

G4 vs. G5 confusion?
Is it possible we are getting G4 and G5 confused? Per the DexCom page, it seems like the G4 is for HCP use only? — Preceding unsigned comment added by 50.75.96.154 (talk) 20:56, 8 June 2016 (UTC)

Tags
It is my opinion that I believe we should get rid of “this page may not meet Wikipedia's notability guidelines for companies and organizations.” Because their is clearly multiple news outlets talking about Dexcom  in recent months. BigRed606 (talk) 03:36, 2 October 2019 (UTC)

History and Product Generations
During February 2009, Dexcom received approval for the Seven Plus Continuous Glucose Monitor, of its new continuous glucose monitoring system from the FDA. This product received a CE mark in November 2009. Dexcom’s first G-series CGM, the G4 Platinum, received a CE mark and FDA approval in 2012 for adults ages 18 and over. This new device improved hypoglycemic accuracy by 30% It also offered a longer range of transmission between the sensor and receiver as well as a color LCD display. The G4 Platinum was later approved by the FDA for use in patients ages 2-17 in February 2014. Dexcom then received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the “Share” and “Follow” smartphone apps. The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, and unlike previous generations, the G5 had Bluetooth built into the transmitter, enabling it to send data to the a mobile device. This allowed for use of the device without the standalone receiver. The Dexcom G5 then received a CE Mark in September 2015.

The Dexcom G6 gained FDA authorization and a CE Mark in 2018. The device is indicated as an integrated continuous glucose monitor (iCGM) system by the FDA for use as both a standalone CGM and for integration into automated insulin dosing (AID) systems. It is the first CGM to receive the iCGM classification by the FDA. The G6 is worn on the abdomen and continuously measures blood glucose levels in the body’s interstitial fluid, sending the readings to a dedicated receiver or compatible smartphone. It is factory-calibrated and does not require routine fingersticks The water-resistant sensor is approved for use for 10 days, compared to 7 days with the G5. It is intended for use by people with diabetes age two years and older.

The Dexcom G6 Pro, which received FDA approval in October 2019, is the only single use, professional CGM that gathers real-time glucose data over a 10-day period and offers both a blinded and unblinded mode. In blinded mode, the healthcare provider has access to the CGM data while the patient will not have direct access. In blinded mode, patients are able to review their CGM data with their healthcare provider at the end of the 10-day session. In unblinded mode, patients are able to see their glucose data throughout the 10-day duration.

Partnerships
Dexcom entered a non-exclusive agreement with Tandem Diabetes Care, Inc. in 2015 to allow the integration of its new G5 and G6 continuous glucose monitoring systems into Tandem's insulin pumps. In June 2019, Dexcom announced a collaboration with Companion Medical to enable the exchange of CGM data from Dexcom with insulin data from InPen™ into both companies’ software applications.

Tandem Diabetes Care received FDA approval in December 2019 for Control-IQ, a closed-loop technology that uses Tandem’s t:slim X2 insulin pump and the Dexcom G6 to “to automatically increase, decrease, or stop the delivery of insulin in response to the glucose levels of people with Type 1 diabetes.” Dexcom entered into a partnership with Livongo, a digital chronic care management company, in January 2020 to share CGM data from the Dexcom G6 with Livongo’s platform. This integration will allow Livongo to incorporate the CGM data along with other patient data to provide health insights based on its algorithm to help patients manage their diabetes. In February 2020, Dexcom and Insulet Corporation signed a non-exclusive, global agreement to combine current and future Dexcom continuous glucose monitoring systems with Insulet’s tubeless insulin delivery Pod into the Omnipod Horizon™ System for automated insulin delivery. This will give the ability to adjust insulin doses based on Insulet’s algorithm or through their smartphone. The company also announced in March 2020 a partnership with Welldoc to integrate G6 CGM data with BlueStar, a digital platform for diabetes management. BlueStar will combine the CGM data with information on patients’ activity, nutrition, sleep and other factors to help them manage their condition.

Leadership
Kevin Sayer is Dexcom’s Executive Chairman, President and CEO. Sayer joined Dexcom as president in 2011 and became CEO in 2015. After Sayer joined the executive team, Dexcom’s expansion of the G4 product helped drive a 60% increase in annual revenue to $160 million. Dexcom reported annual revenue of $1.48 billion for 2019. Chistina.mlynski (talk) 17:00, 8 June 2020 (UTC)